TS SOI gains ground in the European implant market

Osstem Implant introduced its TS SOI implant system in Europe in November 2021. Developed with product performance, clinical reliability and long-term stability as central considerations, the system combines features intended to support strong primary stability and early osseointegration—established clinical priorities that may contribute to long-term treatment success.

Osstem has projected that sales of the TS SOI implant system across 16 European markets will grow at a compound annual rate of approximately 48% between 2023 and 2026.
Osstem Implant

TS SOI implant system combining SOI surface technology with a self-tapping dual-thread design — TS SOI combines Osstem Implant’s SOI surface technology with a self-tapping, dual-thread implant design intended to support primary stability and early healing.

At the core of the implant system is its super-hydrophilic SOI surface technology, which is designed to allow blood to spread rapidly across the implant surface. According to Osstem, this may facilitate early blood clot formation and osteoblast attachment during the healing phase. These surface characteristics are intended to promote early osseointegration.

The data covers Bosnia-Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Montenegro, North Macedonia, Norway, Poland, Romania, Serbia, Slovakia and Slovenia.

TS SOI also incorporates a self-tapping design, a dual thread and optimised body geometry to support placement and primary stability. These design features are intended to increase engagement with the surrounding bone during implant placement and improve load distribution. Depending on bone quality, surgical protocol and case selection, the system may be used in sites with compromised bone quality and in treatment scenarios involving immediate or early loading, subject to the applicable instructions for use.

In suitable cases, adequate primary stability and early osseointegration may support shorter treatment times and more predictable healing. Treatment duration and outcomes also depend on patient-related, surgical and prosthetic factors. Osstem continues to expand its implant portfolio in Europe, and TS SOI forms part of its range of systems intended to support primary stability and early healing.

TS SOI implant in clinical use — SOI surface technology is designed to support early blood clot formation and osseointegration.

Osstem TS SOI implant — The TS SOI implant combines a hydrophilic surface with a self-tapping, dual-thread body.

Osstem Implant marks 20 years of global market expansion

Osstem Implant has expanded its global presence from an initial network of 12 overseas subsidiaries established in 2006 to 33 entities across 29 countries. Over the past two decades, the company has built a solid foundation for sustainable growth in international markets by leveraging its strengths in research and development, a structured clinical education system and a direct-sales business model.

Following two decades of sustained expansion, Osstem Implant now ranks third globally in implant market share.
Osstem Implant

Osstem clinical education programmes completed by more than 150,000 dentists globally — According to Osstem Implant, its clinical education programmes, including its master course, have been completed by more than 150,000 dentists globally.

Osstem Implant’s international expansion began in the mid-2000s. Starting with Taiwan in 2005, the company established its first wave of overseas subsidiaries across 12 countries—Germany, India, Russia, China, Hong Kong, Singapore, Japan, the US, Thailand and Malaysia in 2006, followed by Australia in 2007. These subsidiaries developed product portfolios tailored to local market conditions and clinical environments, and localised clinical education and sales expertise.

These early overseas operations laid the groundwork for Osstem Implant’s current global footprint, which includes an export network reaching more than 100 countries. This year, Osstem Implant marks 20 years since the start of its international expansion and plans to further accelerate overseas market development.

Osstem Implant attributes its international growth to three core strengths: product quality supported by sustained R&D investment, a business model enabling close engagement with dental professionals, and a comprehensive clinical education system. Since its founding, the company has invested approximately 11% of annual revenue in R&D. Its central research institute comprises about 30,000 m² of research facilities, including around 10,000 m² of laboratory space, and employs more than 900 researchers.

The flagship Osstem Master Course follows a step-by-step curriculum aligned with dentists’ levels of clinical experience. More than 150,000 dentists worldwide have completed its education programmes to date. A direct-sales structure in overseas markets has supported close communication between local subsidiaries and clinicians, and the company says it will continue to strengthen locally driven strategies across R&D, education and sales.